drug
Tyvaso DPI
Marketedupdated 3mo agoby $UTHR UNITED THERAPEUTICS Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 6Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for recurrent thrombophlebitis and pulmonary arterial hypertension and 16 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying Tyvaso DPI
- phase3Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- phase4A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
- phase1A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
- phase2A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks
- —TREPROSTINIL in Pulmonary Hypertension: Evidence and Clinical Trends
- phase3Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
- phase3Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- phase2Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 14, 2027
271 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (80)
- Feb 3, 2042method-of-use (U-3749)US 11826327
- Feb 3, 2042method-of-use (U-3749)US 11826327
- Feb 3, 2042method-of-use (U-3749)US 11826327
- Feb 3, 2042method-of-use (U-3749)US 11826327
- Feb 3, 2042method-of-use (U-3749)US 11826327
- Feb 3, 2042method-of-use (U-3749)US 11826327
- Apr 1, 2035formulationUS 10421729
- Apr 1, 2035formulationUS 10421729
- Apr 1, 2035formulationUS 10421729
- Apr 1, 2035formulationUS 10421729
- Apr 1, 2035formulationUS 10421729
- Jun 11, 2030formulationUS 107728833.8y
- Jun 11, 2030formulationUS 107728833.8y
- Jun 11, 2030formulationUS 107728833.8y
- Jun 11, 2030formulationUS 107728833.8y
- Jun 11, 2030formulationUS 107728833.8y
- Mar 29, 2029formulationUS 79990072.6y
- Mar 29, 2029formulationUS 79990072.6y
- Mar 29, 2029formulationUS 79990072.6y
- Mar 29, 2029formulationUS 79990072.6y
- Mar 29, 2029formulationUS 79990072.6y
- Mar 29, 2029formulationUS 79990072.6y
- Mar 29, 2029formulationUS 79990072.6y
- Mar 29, 2029formulationUS 79990072.6y
- Dec 15, 2028compositionUS 117238872.3y
- Dec 15, 2028compositionUS 117238872.3y
- Dec 15, 2028compositionUS 117238872.3y
- Dec 15, 2028compositionUS 117238872.3y
- Dec 15, 2028compositionUS 117238872.3y
- Dec 15, 2028compositionUS 117238872.3y
- Dec 15, 2028compositionUS 117238872.3y
- Dec 15, 2028compositionUS 117238872.3y
- Dec 15, 2028compositionUS 117238872.3y
- Dec 15, 2028compositionUS 117238872.3y
- Dec 15, 2028compositionUS 117238872.3y
- Dec 15, 2028compositionUS 117238872.3y
- Dec 15, 2028compositionUS 117238872.3y
- Dec 15, 2028compositionUS 117238872.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Dec 15, 2028compositionUS 95930662.3y
- Sep 5, 2028method-of-use (U-1437)US 86531372.1y
- Sep 5, 2028method-of-use (U-1437)US 86531372.1y
- Sep 5, 2028method-of-use (U-1437)US 86531372.1y
- Sep 5, 2028method-of-use (U-1437)US 86531372.1y
- Sep 5, 2028method-of-use (U-1437)US 86531372.1y
- Sep 5, 2028method-of-use (U-1437)US 86531372.1y
- Sep 5, 2028method-of-use (U-1437)US 86531372.1y
- Sep 5, 2028method-of-use (U-1437)US 86531372.1y
- Sep 5, 2028method-of-use (U-1437)US 86586942.1y
- Sep 5, 2028method-of-use (U-1437)US 86586942.1y
- Sep 5, 2028method-of-use (U-1437)US 86586942.1y
- Sep 5, 2028method-of-use (U-1437)US 86586942.1y
- Sep 5, 2028method-of-use (U-1437)US 86586942.1y
- Sep 5, 2028method-of-use (U-1437)US 86586942.1y
- Sep 5, 2028method-of-use (U-1437)US 86586942.1y
- Sep 5, 2028method-of-use (U-1437)US 86586942.1y
- May 5, 2028method-of-use (U-1849)US 93582401.7y
- Mar 10, 2028formulationUS 93395071.6y
- May 14, 2027method-of-use (U-1849)US 10376525271d
- May 14, 2027method-of-use (U-1849)US 11357782271d
- May 14, 2027method-of-use (U-1849)US 11357782271d
- May 14, 2027method-of-use (U-1849)US 11357782271d
- May 14, 2027method-of-use (U-1849)US 11357782271d
- May 14, 2027method-of-use (U-1849)US 11357782271d
News(2)
- Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advancesThe new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched…biopharma_dive · 28d ago
- Insmed moves closer to $6B opportunity as PAH drug shows long-term durabilityInsmed’s inhalable candidate showed “impressive” long-term efficacy in pulmonary arterial hypertension, according to analysts at Guggenheim Partners, with functional and biomarker improvements thro…biospace · 29d ago
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that